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doi:10.1016/j.rmedc.2009.02.004We report a case of pneumonia due to Tsukamurella pulmonis in
a 76-year-old immunocompetent woman with chronic pulmonary
disease. Microbiological diagnosis was made by bacteriological and
molecular means and infection was cured by empirical antibiotic
treatment. This work highlights the potential role of Tsukamurella
in pathogenesis of pneumonia in immunocompetent patients.1. Case report
A 76-year-old womanwith chronic respiratory failure in chronic
obstructive pulmonary disease (COPD) arrived at the accident and
emergency department with a 2-day history of altered state of
consciousness and increasing dyspnoea.
Her medical history included: long history of use of tobacco
(34.5 pks/yr), domiciliary oxygen therapy, obesity, diabetes melli-
tus well-controlled by oral hypoglycaemic drugs, systemic arterial
hypertension, bilateral glaucoma, left nephrectomy for kidney
stone complicated by acute renal failure, without history of
immunodeﬁcits and allografts.
The ﬁrst examination revealed that the patient was apyretic,
dyspnoeic, tachypnoeic, with a blood pressure of 130/70 mmHg,
and respiratory rate of 38 breaths per min. The patient appearedailing address: Pulmonary
cred Heart, Largo Gemelli 8,
6 30154304.
olo).
All rights reserved.confused, responsive to painful stimuli. On auscultation lower
pulmonary ﬁelds were ipophonetic and vescicular murmur was
reduced bibasaly. Laboratory examinations, chest radiograph (CXR)
and blood gas analysis (BGA) were performed. BGA results were:
FiO2: 0.50, paO2: 129 mmHg, pCO2: 110 mmHg, pH: 7.24. CXR
showed: large patchy areas of bilateral alveolar involvement with
ground-glass like features in the anterior segment of right upper
lobe. Paracardiac parenchyma of right lower lobe, lower two-thirds
of the left lung parenchyma, lingula (silhouette sign) and lower left
lobe (air-bronchogram sign) showed alveolar involvement with
both ground-glass and consolidation like features. Moreover, small
bilateral effusion and radiographic signs of COPD were present
(Fig. 1A).
In Intensive Care Unit (ICU), the patient underwent a trial of
non-invasivemechanical ventilationwithout beneﬁt and thereafter
the patient underwent oro-tracheal intubation and was mechan-
ically ventilated for 3 days. She was started on empirical antibiotic
treatment with amoxicillin–clavulanic acid and azithromycin
immediately after bronchoalveolar lavage (BAL) cultures.
The general clinical improvement allowed the transfer to the
department of Pulmonary Medicine. At arrival the patient was
eupnoic, had productive cough and bilateral leg oedema. BGA
results were: FiO2: 0.31, paO2: 71.4 mmHg, pCO2: 63.3 mmHg, pH:
7.36, HCO3-: 31.8 mmol/L, BE: 8.2 mmol/L. She underwent a new
trial of non-invasive ventilation (mode: pressure support, inspira-
tory positive airway pressure: 16 cmH2O, espiratory positive airway
pressure: 6 cmH2O, target volume: 350 mL, and with supplemental
oxygen of 2 litres per min.), with good compliance and
Fig. 1.
Fig. 2.
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immediately after hospital admission in ICU, yielded Staphylococcus
epidermidis sensitive to ciproﬂoxacin. Cultures of sputum sample,
performed within 48 hours after the transfer to the department of
Pulmonary Medicine, yielded Pseudomonas aeruginosa and Steno-
trophomonas maltophilia, both sensitive to ciproﬂoxacin and levo-
ﬂoxacin. Then, antibiogram-guided therapy was started:
azithromicin was replaced with ciproﬂoxacin, while amoxicillin–
clavulanic acid was continued. Both BAL and sputum sample were
processed for isolation of mycobacteria following standard proce-
dures.7 After 1 week it was observed a general clinical improve-
ment: BGA results were: FiO2: 0.28, paO2: 69.8 mmHg, pCO2:
53.8 mmHg, pH: 7.39, HCO3
: 30.3 mmol/L, and BE: 6.6 mmol/L.
However, CXR still showed: reduced bilateral pleural effusion with
residual basal ipoventilation. Both cultures from BAL and the
sputum sample, processed for isolation of mycobacteria, yielded
a positive culture in MGIT 960 (Becton Dickinson) and in Low-
enstein–Jensen. The strain isolated in culture was subjected to
Ziehl–Nielsen staining, showing a weak acid–alcohol-fast staining
and a rod shape. Subculture was observed in Trypticase Soy agar,
Middlebrook 7H11 agar, nutrient agar, and MacConkey agar
without crystal violet, with an abundant growth in the ﬁrst
48 hours. Colonies were not-pigmented (white-cream) and ranged
in size from 2 to 5 mm in diameter (Fig. 2). The microorganism
grew at 28 and 35 C but not at 42 C. Based on these observation
there were strong indication for an atypical, rapidly growing,
Mycobacterium spp., but no mycobacteria were identiﬁed. A nega-
tive result with the Quantiferon Test excluded an infection byM. tuberculosis. To properly identify the microorganism, genomic
DNA was extracted from the isolate with the Qiagen EZ1 tissue kit,
following the manufacturer’s instructions, and the 16S RNA DNA
was ampliﬁed by PCR and subjected to automated gene
sequencing.3,6 The results obtained identiﬁed themicroorganism as
T. pulmonis. Biochemical tests such as semi-quantitative catalase
and 68 C heat-stable catalase conﬁrmed the molecular results and
the phenotypic identiﬁcation using the API Coryne system, RapID
CB Plus system and API 20 C AUX system led to the biochemical
identiﬁcation with the numerical proﬁle of, 2150004, 0627511,
6042160, respectively.
Drug susceptibility test was performed by E-test diffusion agar
method (ABBIODISK, Solna, Sweden), yielding the followingMICs:VAN
4 mg/ml; IPM>32 mg/ml; CLR 2 mg/ml; LVX 0.35 mg/ml; PEN>4 mg/ml;
AMC >32 mg/ml; ERY 2 mg/ml; TET 2 mg/ml and CIP 0,25 mg/ml.
The patient was discharged and continued ciproﬂoxacin for 10
days and after 2 months, she performed a follow-up visit at our
Ambulatory of Respiratory Medicine: physical examination
revealed that the patient was apyretic, eupnoeic, respiratory rate of
24 breaths permin, and chest examinationwas normal; BGA results
were: FiO2: 0.21, paO2: 69.4 mmHg, pCO2: 43.6 mmHg, pH: 7.40.
CXR showed: complete resolution of alveolar and pleural involve-
ment (Fig. 1B).2. Discussion
The genus Tsukamurella was ﬁrst described by Collins et al. in
1988 following the reclassiﬁcation and further molecular and
phenotypic characterization of Gordiana aurantiaca, Rhodococcus
aurantiaca and other related organisms including Corynebacterium
paurometabola, which were distinct from the other mycolic acid-
containig actinomycetes.4
The genus is phylogenetically related to the genera Nocardia,
Gordonia, Streptomyces, Rhodococcus, Corynebacterium and Myco-
bacterium and taxonomically comprises of at least eight described
species including T. inchonensis, T. paurometabola, T. pseudospumae,
T. pulmonis, T. spumae, T. strandjordii, T. tyrosinosolvens and
T. wratislaviensis.2
Tsukamurella is a Gram-positive, variable rod-shaped, weakly
acid–alcohol-fast, non-motile, aerobic bacterium. It has been
reported as a cause of infections in humans with immunosup-
pression and indwelling foreign bodies. It has also been isolated in
one patient with AIDS (Acquired Immunodeﬁciency Syndrome) as
a saprophytic organism.
Microbiological diagnosis of Tsukamurella sp. is cumber-
some,1,5,9 duemostly to the similarity of Tsukamurella to other more
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mised patients, such as Mycobacteria. The implementation of
molecular identiﬁcation by sequencing of the 16S rRNA gene may
be particularly useful and may lead to a correct diagnosis in a short
time frame.
Tsukamurella infections have emerged over the last decade as
a rare but signiﬁcant cause of serious infection in immunocom-
promised patient.8 Moreover there has been a report of the colo-
nization of a patient with T. pulmonis subsequent to a M.
tuberculosis infection.10
In our case, lung infection could not be attributed to either P.
aeruginosa or to S. maltophilia because theywere not present in BAL
performed at admission in ICU. Therefore, the detection of these
bacteria outlines nosocomial infection. Finally, the detection of T.
pulmonis and S. epidermidis on BAL sample makes the ﬁrst bacte-
rium responsible for the lung infection, although both are suscep-
tible to the same antibiotic.
To our knowledge, this is the ﬁrst case of respiratory infection
from T. pulmonis in an immunocompetent patient, at risk as
diabetic.
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